Langston, UCO receive new research designation from national group
A change in the way two national organizations recognize the research done at universities has resulted in two Oklahoma schools receiving a prestigious designation.
Langston University and the University of Central Oklahoma were among 216 schools that received the new 'Research Colleges and Universities' designation in the Carnegie Classification, which is administered by the American Council on Education and the Carnegie Foundation for the Advancement of Teaching.
Since 1973, the Carnegie Classification has been the leading framework for recognizing and describing institutional diversity in higher education across the U.S. The classifications are updated every three years and give institutions designations based on their sizes, types of degrees conferred and many other such characteristics.
The University of Oklahoma and Oklahoma State University — the state's two largest universities — long have been considered the state's only research universities, earning a so-called 'R1' rating in the Carnegie Classification. That places OSU and OU among 187 institutions that, on average in a single year, spend at least $50 million research and development and award at least 70 research doctorates.
There's also a R2 rating, for schools spend at least $5 million on research and development and award at least 20 research doctorates. But many smaller schools don't have the resources to spend that much on research or have limited (or no) doctoral programs, or both. UCO and Langston each fall into that category.
But last month, the Carnegie Foundation and ACE released the first phase of the redesigned Carnegie Classifications, to more fully recognize the amount of research underway at institutions without a R1 or R2 designation. They said the change came in an attempt to better account for and reflect what it called 'the multifaceted research landscape within U.S. higher education.'
'A highlight of our work to modernize the Carnegie Classification is the new Research Colleges and Universities designation, which will shed light on institutions that have engaged in research but historically haven't been recognized for it,' said Ted Mitchell, president of ACE. 'Instead of limiting research designations to the select institutions that award Ph.D.s, all types of colleges and universities will now be celebrated for their research contributions. That's great news.'
In academic circles, Langston — a historically Black land-grant university in rural Logan County near the town that shares a name with the school — probably is best known for its E. (Kika) de la Garza American Institute for Goat Research, but it also has research programs for horticulture and agronomy, aquaculture and aquaponics, biotechnology, and agribusiness and rural economic development, among others.
Langston's Rehabilitation Research and Training Center was renewed for a third five-year cycle of funding from the National Institute on Disability, Independent Living, and Rehabilitation Research in late 2023.
Langston President Ruth Ray Jackson said schools with the Research Colleges and Universities designation spend at least $2.5 million annually on research and development. She said the university spent about $10.5 million on research in fiscal year 2023. The university offers only one doctoral program, the Doctor of Physical Therapy, which is a professional, not a research, doctorate.
'This recognition highlights the hard work and dedication of our researchers, faculty and staff who strive to strengthen the academy,' said Alonzo Peterson, Langston's vice president for academic affairs. 'We have very smart people at Langston University. I am always inspired when I visit the labs or sit down with my colleagues.'
Similarly, UCO fits neatly into the new Carnegie Classifications designation. Located in Edmond, UCO has only one doctoral program, in forensic science, but is in the exploratory/planning stages for other professional doctorate degrees, spokeswoman Adrienne Nobles said.
UCO spent an average of $7.05 million annually on research projects during the past three years.
'Research conducted at University of Central Oklahoma moves our state and nation forward. For years, our faculty and students have engaged in innovative and impactful research on the undergraduate and graduate level,' UCO President Todd Lamb said.
'This new classification formally recognizes and elevates our ongoing mission to transform students through education, preparing them to meet the critical needs of our communities. UCO has the momentum to become a driving force for academic research in Oklahoma.'
UCO offers 115 undergraduate and 78 graduate programs to more than 12,500 students.
This article originally appeared on Oklahoman: Langston, UCO receive new research designation from national group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
New paper sheds light on experience of Black prisoners in infamous Stateville prison malaria experiments
Much has been said and written over the years about controversial malaria research conducted on inmates at Illinois' Stateville Penitentiary starting in the 1940s. But at least one part of that story has been largely ignored until now: the role of Black prisoners in that research, which helped lead to the modern practice of using genetic testing to understand how individual patients will react to certain medications, according to the authors of a newly published paper out of the University of Utah. 'We want to highlight the stories of Black prisoners that participated in this prison research in the 1950s onward and give them their due,' said Hannah Allen, a medical ethicist and assistant professor of philosophy at the University of Texas Rio Grande Valley, and first author of the paper, which was published as an opinion piece Wednesday in the Journal of the American Medical Association. 'They haven't been properly acknowledged in the past, and their participation in these studies was really foundational in launching the field of pharmacogenetics and, later on, precision medicine,' said Allen, who recently completed her doctorate at the University of Utah. Starting in the 1940s, researchers infected inmates at the Joliet-area prison with malaria to test the effectiveness of drugs to treat the illness as part of a U.S. military-funded effort to protect American troops overseas, according to the paper. A University of Chicago doctor was the principal investigator. The inmates consented to being part of the studies and were paid for their participation. At first, the research was greeted with enthusiasm. In 1945, Life magazine ran a spread about it, featuring a photo of a Stateville inmate with cups containing malaria-carrying mosquitoes pressed against his bare chest. The first line of the story reads, 'In three U.S. penitentiaries men who have been imprisoned as enemies of society are now helping science fight another enemy of society.' But as the years passed, attitudes began to shift. Questions arose about whether inmates could truly, freely consent to participate in medical experiments or whether they felt coerced into them because of their often dire circumstances. At the Nuremberg trials, defense attorneys for Nazi doctors introduced text and images from the Life article about Stateville prison, though an Illinois physician argued at the trials that the prisoners in Stateville consented to being part of medical research whereas Nazi prisoners did not, according to the JAMA paper. In the mid-1970s, news broke about a study at Tuskegee, in which Black men with syphilis went untreated for years — news that raised awareness of ethical problems in medical research. News outlets also began publishing more stories about prison research, according to the JAMA article. The Chicago Tribune published an article in 1973, in which an inmate participating in the Stateville malaria research said: 'I've been coerced into the project — for the money. Being here has nothing to do with 'doing good for mankind' … I didn't want to keep taking money from my family.' The experiments at Stateville came to a halt in the 1970s. A number of protections and regulations are now in place when it comes to research involving prisoners. Since the 1970s, the Stateville research has often been discussed and analyzed but little attention has been paid to its Black participants, said James Tabery, a medical ethicist and philosophy professor at the University of Utah who led the new research, which was funded by the federal National Institutes of Health. For a time, Black prisoners were excluded from the studies because of a myth that Black people were immune to malaria, Tabery said. Later on, once scientists had pinpointed the drug primaquine as an effective medication for malaria, they turned their attention to the question of why 5% to 10% of Black men experienced a violent reaction to the drug, according to the paper. Ultimately, the scientists were successful, finding that the adverse reaction was related to a specific genetic deficiency. 'There are people all over Chicago today that are getting tested, that clinicians are recommending they get a genetic test before they get prescribed a drug because they want to make sure that their patient isn't going to have an adverse reaction to the drug,' Tabery said. 'It's really sort of powerful and interesting that you can trace that approach to doing good clinical medicine right back to this particular moment and place and population.' But Tabery and Allen also found that the Black prisoners were not treated the same as the white prisoners who participated in research at Stateville. For one, they weren't paid as much as the white prisoners, the rationale being that the white prisoners were infected with malaria, whereas the Black prisoners were given the drug but not infected with the disease — though some of the Black prisoners got very ill after taking the medication, according to the paper. Also, researchers didn't protect the Black participants' privacy as well as they did for other participants. They published certain identifying information about the Black participants, such as initials, ages, heights and weights, whereas participants in the previous research were represented with case numbers, according to the paper. Researchers also recruited the Black prisoners' family members for the study, which they didn't do with earlier participants, according to the paper. 'You see them just doing things with the Black prisoners that they're not doing with the white prisoners,' Tabery said. Also, though scientists made an important discovery through the research on Black prisoners, the episode also highlights the difficulty that can occur in translating discoveries into real life help for patients. Though the World Health Organization now recommends genetic testing to protect people who are sensitive to antimalarials, many of the people who would benefit most from such testing still don't receive it because of financial barriers, supply chain issues and a lack of training, according to the paper. 'What we found is when you sort of shift to what was happening to the Black prisoners, these other lessons you hadn't thought of as being derivable from Stateville suddenly do become apparent,' Tabery said.
Chicago Tribune
7 hours ago
- Chicago Tribune
New paper sheds light on experience of Black prisoners in infamous Stateville prison malaria experiments
Much has been said and written over the years about controversial malaria research conducted on inmates at Illinois' Stateville Penitentiary starting in the 1940s. But at least one part of that story has been largely ignored until now: the role of Black prisoners in that research, which helped lead to the modern practice of using genetic testing to understand how individual patients will react to certain medications, according to the authors of a newly published paper out of the University of Utah. 'We want to highlight the stories of Black prisoners that participated in this prison research in the 1950s onward and give them their due,' said Hannah Allen, a medical ethicist and assistant professor of philosophy at the University of Texas Rio Grande Valley, and first author of the paper, which was published as an opinion piece Wednesday in the Journal of the American Medical Association. 'They haven't been properly acknowledged in the past, and their participation in these studies was really foundational in launching the field of pharmacogenetics and, later on, precision medicine,' said Allen, who recently completed her doctorate at the University of Utah. Starting in the 1940s, researchers infected inmates at the Joliet-area prison with malaria to test the effectiveness of drugs to treat the illness as part of a U.S. military-funded effort to protect American troops overseas, according to the paper. A University of Chicago doctor was the principal investigator. The inmates consented to being part of the studies and were paid for their participation. At first, the research was greeted with enthusiasm. In 1945, Life magazine ran a spread about it, featuring a photo of a Stateville inmate with cups containing malaria-carrying mosquitoes pressed against his bare chest. The first line of the story reads, 'In three U.S. penitentiaries men who have been imprisoned as enemies of society are now helping science fight another enemy of society.' But as the years passed, attitudes began to shift. Questions arose about whether inmates could truly, freely consent to participate in medical experiments or whether they felt coerced into them because of their often dire circumstances. At the Nuremberg trials, defense attorneys for Nazi doctors introduced text and images from the Life article about Stateville prison, though an Illinois physician argued at the trials that the prisoners in Stateville consented to being part of medical research whereas Nazi prisoners did not, according to the JAMA paper. In the mid-1970s, news broke about a study at Tuskegee, in which Black men with syphilis went untreated for years — news that raised awareness of ethical problems in medical research. News outlets also began publishing more stories about prison research, according to the JAMA article. The Chicago Tribune published an article in 1973, in which an inmate participating in the Stateville malaria research said: 'I've been coerced into the project — for the money. Being here has nothing to do with 'doing good for mankind' … I didn't want to keep taking money from my family.' The experiments at Stateville came to a halt in the 1970s. A number of protections and regulations are now in place when it comes to research involving prisoners. Since the 1970s, the Stateville research has often been discussed and analyzed but little attention has been paid to its Black participants, said James Tabery, a medical ethicist and philosophy professor at the University of Utah who led the new research, which was funded by the federal National Institutes of Health. For a time, Black prisoners were excluded from the studies because of a myth that Black people were immune to malaria, Tabery said. Later on, once scientists had pinpointed the drug primaquine as an effective medication for malaria, they turned their attention to the question of why 5% to 10% of Black men experienced a violent reaction to the drug, according to the paper. Ultimately, the scientists were successful, finding that the adverse reaction was related to a specific genetic deficiency. 'There are people all over Chicago today that are getting tested, that clinicians are recommending they get a genetic test before they get prescribed a drug because they want to make sure that their patient isn't going to have an adverse reaction to the drug,' Tabery said. 'It's really sort of powerful and interesting that you can trace that approach to doing good clinical medicine right back to this particular moment and place and population.' But Tabery and Allen also found that the Black prisoners were not treated the same as the white prisoners who participated in research at Stateville. For one, they weren't paid as much as the white prisoners, the rationale being that the white prisoners were infected with malaria, whereas the Black prisoners were given the drug but not infected with the disease — though some of the Black prisoners got very ill after taking the medication, according to the paper. Also, researchers didn't protect the Black participants' privacy as well as they did for other participants. They published certain identifying information about the Black participants, such as initials, ages, heights and weights, whereas participants in the previous research were represented with case numbers, according to the paper. Researchers also recruited the Black prisoners' family members for the study, which they didn't do with earlier participants, according to the paper. 'You see them just doing things with the Black prisoners that they're not doing with the white prisoners,' Tabery said. Also, though scientists made an important discovery through the research on Black prisoners, the episode also highlights the difficulty that can occur in translating discoveries into real life help for patients. Though the World Health Organization now recommends genetic testing to protect people who are sensitive to antimalarials, many of the people who would benefit most from such testing still don't receive it because of financial barriers, supply chain issues and a lack of training, according to the paper. 'What we found is when you sort of shift to what was happening to the Black prisoners, these other lessons you hadn't thought of as being derivable from Stateville suddenly do become apparent,' Tabery said.
Medscape
12 hours ago
- Medscape
Vitiligo in Children Linked to Higher Hearing Loss
Children with vitiligo showed higher risks for sensorineural hearing loss (SNHL) and mixed hearing loss compared with matched peers in a study, but not with ocular conditions. METHODOLOGY: The study analyzed data on pediatric patients with vitiligo from 89 healthcare organizations in the US through the TriNetX Research Network between 2016 and 2024. There were 21,833 pediatric patients with vitiligo (mean age, 9.6 years; 50.1% boys) and an equal number of matched children without vitiligo. Nearly 45% of participants in both groups were White, about 27% were Hispanic or Latino, about 14% were Black, and 6.6% were Asian. The primary outcomes were hearing loss and ocular disorders. TAKEAWAY: Children with vitiligo showed significantly higher risks for SNHL (hazard ratio [HR], 1.86; 95% CI, 1.38-2.51) and mixed hearing loss (HR, 2.10; 95% CI, 1.29-3.44) compared with children without vitiligo. No significant difference was observed for conductive hearing loss between the two groups. SNHL risk increased with time after the first year of follow-up, with an HR of 2.03 (95% CI, 1.21-3.41) for 1-3 years, and 2.56 (95% CI, 1.55-4.22) for follow-up periods longer than 3 years. The risk for mixed hearing loss was elevated only in the first year (HR, 4.87; 95% CI, 1.65-14.4). Researchers found an elevated risk for retinal and choroidal disorders (HR, 1.56; 95% CI, 1.06-2.31), but this was not consistent in sensitivity analyses. There were no significant differences in the risks for vision impairment, dry eye, uveitis, or glaucoma between the two groups. IN PRACTICE: 'Our observation of increased SNHL risk, particularly after the first year of follow-up, aligns with the theory that hearing loss develops progressively through cumulative cochlear damage, correlating with disease duration and extent,' the study authors wrote. 'Further prospective studies are needed to illuminate the mechanisms underlying these associations and guide clinical practice,' they added. SOURCE: This study was led by Serena Yun-Chen Tsai, MD, MMSc, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School in Boston, and was published online on June 11 in JAMA Dermatology . LIMITATIONS: This study was limited by its retrospective design; reliance on the International Classification of Diseases, 10th Revision, Clinical Modification codes; and the absence of data regarding vitiligo severity, phenotypes, location, audiometry findings, and visual function measurements. Dermatologist diagnoses or referrals were not verified, and the rarity of some outcomes could have introduced bias. DISCLOSURES: This study's funding source was not disclosed. One author reported receiving grants, personal fees, and consulting fees from multiple pharmaceutical companies, including Incyte, Barinthus Biotherapeutics, Alys Pharmaceuticals, and AbbVie; being a founder and owning stocks in Alys Pharmaceuticals and Incyte; and serving as chief innovation officer for Alys Pharmaceuticals. Another author reported serving on the advisory board for Sanofi and receiving a salary from a Weston Career Development Award from the Society for Pediatric Dermatology and the Pediatric Dermatology Research Alliance.
